Novartis Q1 2024 Adj EPS $1.80 Beats $1.67 Estimate, Sales $11.829B Beat $11.433B Estimate
Portfolio Pulse from Benzinga Newsdesk
Novartis (NYSE:NVS) reported Q1 2024 adjusted EPS of $1.80, surpassing the $1.67 estimate, and sales of $11.829B, exceeding the $11.433B estimate. This represents a 16.88% increase in EPS and an 8.68% decrease in sales from the same period last year.
April 23, 2024 | 6:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis reported a strong Q1 2024 with adjusted EPS of $1.80, beating estimates, and sales of $11.829B, also above expectations.
The positive earnings and sales beat by Novartis indicate a strong financial performance, likely leading to a positive short-term impact on its stock price. The significant beat on both top and bottom lines, compared to analyst expectations, suggests operational efficiency and robust demand for its products, which are key drivers for investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100